Cargando…
Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia
SIMPLE SUMMARY: Muscle wasting during cancer is recognized as an independent predictor of mortality. The aim of this study was to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted protei...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693727/ https://www.ncbi.nlm.nih.gov/pubmed/33142864 http://dx.doi.org/10.3390/cancers12113221 |
_version_ | 1783614811802697728 |
---|---|
author | Massart, Isabelle S. Paulissen, Geneviève Loumaye, Audrey Lause, Pascale Pötgens, Sarah A. Thibaut, Morgane M. Balan, Estelle Deldicque, Louise Atfi, Azeddine Louis, Edouard Gruson, Damien Bindels, Laure B. Meuwis, Marie-Alice Thissen, Jean-Paul |
author_facet | Massart, Isabelle S. Paulissen, Geneviève Loumaye, Audrey Lause, Pascale Pötgens, Sarah A. Thibaut, Morgane M. Balan, Estelle Deldicque, Louise Atfi, Azeddine Louis, Edouard Gruson, Damien Bindels, Laure B. Meuwis, Marie-Alice Thissen, Jean-Paul |
author_sort | Massart, Isabelle S. |
collection | PubMed |
description | SIMPLE SUMMARY: Muscle wasting during cancer is recognized as an independent predictor of mortality. The aim of this study was to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. Our study demonstrated that skeletal muscle is a source of several acute phase reactants during cancer cachexia that may hold the key to a cachexia-specific signature. Future work will have to determine whether some of these acute phase reactants contribute to and/or reflect the muscle atrophy caused by cancer, therefore representing potential therapeutic targets and/or biomarkers of cancer cachexia. ABSTRACT: Loss of skeletal muscle mass in cancer cachexia is recognized as a predictor of mortality. This study aimed to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. The changes in the muscle proteome of the C26 model were investigated by label-free proteomic analysis followed by a bioinformatic analysis in order to identify potentially secreted proteins. Multiple reaction monitoring and Western blotting were used to verify the presence of candidate proteins in the circulation. Our results revealed a marked increased muscular production of several acute phase reactants (APR: Haptoglobin, Serine protease inhibitor A3N, Complement C3, Serum amyloid A-1 protein) which are released in the circulation during C26 cancer cachexia. This was confirmed in other models of cancer cachexia as well as in cancer patients. Glucocorticoids and proinflammatory cytokines are responsible for an increased production of APR by muscle cells. Finally, their muscular expressions are strongly positively correlated with body weight loss as well as the muscular induction of atrogens. Our study demonstrates therefore a marked increased production of APR by the muscle in cancer cachexia. |
format | Online Article Text |
id | pubmed-7693727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76937272020-11-28 Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia Massart, Isabelle S. Paulissen, Geneviève Loumaye, Audrey Lause, Pascale Pötgens, Sarah A. Thibaut, Morgane M. Balan, Estelle Deldicque, Louise Atfi, Azeddine Louis, Edouard Gruson, Damien Bindels, Laure B. Meuwis, Marie-Alice Thissen, Jean-Paul Cancers (Basel) Article SIMPLE SUMMARY: Muscle wasting during cancer is recognized as an independent predictor of mortality. The aim of this study was to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. Our study demonstrated that skeletal muscle is a source of several acute phase reactants during cancer cachexia that may hold the key to a cachexia-specific signature. Future work will have to determine whether some of these acute phase reactants contribute to and/or reflect the muscle atrophy caused by cancer, therefore representing potential therapeutic targets and/or biomarkers of cancer cachexia. ABSTRACT: Loss of skeletal muscle mass in cancer cachexia is recognized as a predictor of mortality. This study aimed to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. The changes in the muscle proteome of the C26 model were investigated by label-free proteomic analysis followed by a bioinformatic analysis in order to identify potentially secreted proteins. Multiple reaction monitoring and Western blotting were used to verify the presence of candidate proteins in the circulation. Our results revealed a marked increased muscular production of several acute phase reactants (APR: Haptoglobin, Serine protease inhibitor A3N, Complement C3, Serum amyloid A-1 protein) which are released in the circulation during C26 cancer cachexia. This was confirmed in other models of cancer cachexia as well as in cancer patients. Glucocorticoids and proinflammatory cytokines are responsible for an increased production of APR by muscle cells. Finally, their muscular expressions are strongly positively correlated with body weight loss as well as the muscular induction of atrogens. Our study demonstrates therefore a marked increased production of APR by the muscle in cancer cachexia. MDPI 2020-10-31 /pmc/articles/PMC7693727/ /pubmed/33142864 http://dx.doi.org/10.3390/cancers12113221 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Massart, Isabelle S. Paulissen, Geneviève Loumaye, Audrey Lause, Pascale Pötgens, Sarah A. Thibaut, Morgane M. Balan, Estelle Deldicque, Louise Atfi, Azeddine Louis, Edouard Gruson, Damien Bindels, Laure B. Meuwis, Marie-Alice Thissen, Jean-Paul Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title | Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title_full | Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title_fullStr | Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title_full_unstemmed | Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title_short | Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia |
title_sort | marked increased production of acute phase reactants by skeletal muscle during cancer cachexia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693727/ https://www.ncbi.nlm.nih.gov/pubmed/33142864 http://dx.doi.org/10.3390/cancers12113221 |
work_keys_str_mv | AT massartisabelles markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT paulissengenevieve markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT loumayeaudrey markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT lausepascale markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT potgenssaraha markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT thibautmorganem markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT balanestelle markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT deldicquelouise markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT atfiazeddine markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT louisedouard markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT grusondamien markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT bindelslaureb markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT meuwismariealice markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia AT thissenjeanpaul markedincreasedproductionofacutephasereactantsbyskeletalmuscleduringcancercachexia |